Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altus Formulation Inc.

www.altusformulation.com

Latest From Altus Formulation Inc.

Zohydro Approval Haunts FDA Panelist At Vantrela Meeting

Teva's comparative data suggesting its Vantrela is less attractive to abusers validates advisory committee recommendation in 2012 against Zohydro's approval, advisory committee member says.

BioPharmaceutical United States

Biopharma Quarterly Dealmaking Statistics, Q1 2015

Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.

BioPharmaceutical Deals

Abuse-Deterrent Opioids: FDA Regulatory Options Aired At Meeting

Brand industry favors two- to three-year period for withdrawal or reformulation of products without abuse-deterrent features, while generic industry calls for expedited review pathway. Purdue and Zogenix agree to waive three-year market exclusivity for their respective hydrocodone products.

BioPharmaceutical Clinical Trials

Deals Shaping The Medical Industry, December 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October through November 2013.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Altus Formulation Inc.
  • Senior Management
  • Damon Smith, PhD, CEO
  • Contact Info
  • Altus Formulation Inc.
    Phone: (514) 883-3447
    17800 Rue Lapointe
    Mirabel
    Montreal, 7J7 1P3
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register